Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics Previous close 0.0950
Open 0.0950
Day range —
52-week range 0.0200 0.3400
Off day high 0.00%
Off 52-week high −72.06%
Volume 500
Avg. volume (3M) 1.95K
Market cap 12.02M
EPS (TTM) 1.31
Forward P/E -0.15
P/E ratio (TTM) 0.07
Dividend yield —
Beta (5Y) 0.20
Shares outstanding 126.50M
Short interest 3.96% of float
Earnings date Aug 24, 2017
Analyst target —
Profit margin 0.00%
No recent coverage in the 4Search index.
From articles in the 4Search news index.
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company's lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS…
Sector Healthcare
Industry Biotechnology
Chief executive Irach B. Taraporewala B.S., M.S., Ph.D.
Employees 3
Headquarters Montvale, NJ, United States
Earnings
Next report: Thu, Aug 24, 2017
Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).
Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).
A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.
Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use .